公开(公告)号：US08722110B2

公开(公告)日：2014-05-13

申请号：US13820474

申请日：2011-08-30

申请人： Kyung Seop Ahn ,  Ok-Kyoung Kwon ,  Sei Ryang Oh ,  Jung Hee Kim ,  Hyeong Kyu Lee ,  Mee-Young Lee ,  Hwa-Young Son ,  Kyoung-Youl Lee ,  Soo Yong Kim ,  Giselle Tomayo-Castillo ,  Katia Rosales-Ovares ,  Rodrigo Gamez-Lobo

发明人： Kyung Seop Ahn ,  Ok-Kyoung Kwon ,  Sei Ryang Oh ,  Jung Hee Kim ,  Hyeong Kyu Lee ,  Mee-Young Lee ,  Hwa-Young Son ,  Kyoung-Youl Lee ,  Soo Yong Kim ,  Giselle Tomayo-Castillo ,  Katia Rosales-Ovares ,  Rodrigo Gamez-Lobo

IPC分类号： A01N65/00

CPC分类号： A61K36/44

摘要： Disclosed is a pharmaceutical composition for the prophylaxis and therapy of inflammatory diseases, allergic diseases, or asthma, comprising a velvet apple (Diospyros blancoi A. DC.) extract as an active ingredient. Having the inhibitory activity against the nuclear translocation of NF-κB, whose level is rapidly elevated in response to inflammatory stimuli, the velvet apple extract can suppress the production of NO and PGE2, the expression of iNOS and COX-2, and the release of IL-1β and TNF-α, and can significantly down regulate Th2-mediated IL-4 and IL-13 production. In addition, the extract was found to inhibit the activation of eosinophils in bronchoalveolar lavage fluid, and to suppress the secretion of immunoglobulins and chemokines in bronchoalveolar lavage fluid and blood, as measured by in vivo tests on an ovalbumin-induced asthma mouse model. Therefore, the extract can be used in the method for preventing or treating various inflammatory disorders, allergic diseases, or asthma.

摘要翻译： 公开了一种用于预防和治疗炎性疾病，过敏性疾病或哮喘的药物组合物，其包含天鹅绒苹果（Diospyros blancoi A.DC。）提取物作为活性成分。 天鹅绒苹果提取物对NF-κB的核易位具有抑制活性，其水平迅速升高，可抑制NO和PGE2的产生，iNOS和COX-2的表达，以及 释放IL-1和bgr; 和TNF-α，并可显着下调Th2介导的IL-4和IL-13产生。 此外，发现提取物抑制支气管肺泡灌洗液中嗜酸性粒细胞的活化，并且通过卵清蛋白诱导的哮喘小鼠模型的体内试验测量，抑制支气管肺泡灌洗液和血液中免疫球蛋白和趋化因子的分泌。 因此，提取物可用于预防或治疗各种炎性疾病，过敏性疾病或哮喘的方法。

公开(公告)号：US20130164395A1

公开(公告)日：2013-06-27

申请号：US13820474

申请日：2011-08-30

申请人： Kyung Seop Ahn ,  Ok-Kyoung Kwon ,  Sei Ryang Oh ,  Jung Hee Kim ,  Hyeong Kyu Lee ,  Mee-Young Lee ,  Hwa-Young Son ,  Kyoung-Youl Lee ,  Soo Yong Kim ,  Giselle Tomayo-Castillo ,  Katia Rosales-Ovares ,  Rodrigo Gamez-Lobo

发明人： Kyung Seop Ahn ,  Ok-Kyoung Kwon ,  Sei Ryang Oh ,  Jung Hee Kim ,  Hyeong Kyu Lee ,  Mee-Young Lee ,  Hwa-Young Son ,  Kyoung-Youl Lee ,  Soo Yong Kim ,  Giselle Tomayo-Castillo ,  Katia Rosales-Ovares ,  Rodrigo Gamez-Lobo

IPC分类号： A61K36/44

CPC分类号： A61K36/44

摘要： Disclosed is a pharmaceutical composition for the prophylaxis and therapy of inflammatory diseases, allergic diseases, or asthma, comprising a velvet apple (Diospyros blancoi A. DC.) extract as an active ingredient. Having the inhibitory activity against the nuclear translocation of NF-κB, whose level is rapidly elevated in response to inflammatory stimuli, the velvet apple extract can suppress the production of NO and PGE2, the expression of iNOS and COX-2, and the release of IL-1β and TNF-α, and can significantly down regulate Th2-mediated IL-4 and IL-13 production. In addition, the extract was found to inhibit the activation of eosinophils in bronchoalveolar lavage fluid, and to suppress the secretion of immunoglobulins and chemokines in bronchoalveolar lavage fluid and blood, as measured by in vivo tests on an ovalbumin-induced asthma mouse model. Therefore, the extract can be used in the method for preventing or treating various inflammatory disorders, allergic diseases, or asthma.

摘要翻译： 公开了一种用于预防和治疗炎性疾病，过敏性疾病或哮喘的药物组合物，其包含天鹅绒苹果（Diospyros blancoi A.DC。）提取物作为活性成分。 天鹅绒苹果提取物对NF-κB的核易位具有抑制作用，NF-κB的水平随着炎症刺激而迅速升高，可抑制NO和PGE2的产生，iNOS和COX-2的表达，以及释放 IL-1β和TNF-α，并能显着下调Th2介导的IL-4和IL-13产生。 此外，发现提取物抑制支气管肺泡灌洗液中嗜酸性粒细胞的活化，并且通过卵清蛋白诱导的哮喘小鼠模型的体内试验测量，抑制支气管肺泡灌洗液和血液中免疫球蛋白和趋化因子的分泌。 因此，提取物可用于预防或治疗各种炎性疾病，过敏性疾病或哮喘的方法。

公开(公告)号：US08883226B2

公开(公告)日：2014-11-11

申请号：US13985533

申请日：2012-02-07

申请人： Sei Ryang Oh ,  Kyung Seop Ahn ,  Ok-Kyoung Kwon ,  Hyeong Kyu Lee ,  Joongku Lee ,  Hyouk Joung ,  Mee-Young Lee ,  Hwa-Young Son ,  Kyoung-youl Lee ,  Sang Woo Lee ,  Hang Jin ,  Wan Yi Li

发明人： Sei Ryang Oh ,  Kyung Seop Ahn ,  Ok-Kyoung Kwon ,  Hyeong Kyu Lee ,  Joongku Lee ,  Hyouk Joung ,  Mee-Young Lee ,  Hwa-Young Son ,  Kyoung-youl Lee ,  Sang Woo Lee ,  Hang Jin ,  Wan Yi Li

IPC分类号： A61K36/31

CPC分类号： A61K36/61

摘要： A pharmaceutical composition for the prevention and treatment of inflammatory disease or asthma comprising the extract of Decaspermum fruticosum as an active ingredient. The extract of Decaspermum fruticosum of the present invention inhibited the increase of eosinophils in bronchoalveolar lavage fluid of the ovalbumin induced asthma animal model, had the activity of inhibiting the secretions of immunoglobulin and chemokine (Eotaxin) in bronchoalveolar lavage fluid and blood, and inhibited the secretions of NO and TNF-α in macrophages. Therefore, the extract of Decaspermum fruticosum of the present invention can be effectively used as an active ingredient of a pharmaceutical composition for the prevention and treatment of inflammatory disease or asthma, and of a health functional food for the prevention and improvement of inflammatory disease or asthma.

摘要翻译： 一种用于预防和治疗炎症性疾病或哮喘的药物组合物，其包含作为活性成分的Dececpermum fruticosum的提取物。 本发明的Decaspermum fruticosum的提取物抑制卵清蛋白诱导的哮喘动物模型的支气管肺泡灌洗液中嗜酸性粒细胞的增加，具有抑制支气管肺泡灌洗液和血液中免疫球蛋白和趋化因子（Eotaxin）分泌的活性，并抑制 巨噬细胞中NO和TNF-α的分泌。 因此，本发明的Decaspermum fruticosum的提取物可以有效地用作预防和治疗炎性疾病或哮喘的药物组合物的活性成分，以及用于预防和改善炎性疾病或哮喘的健康功能食品 。

公开(公告)号：US20130323331A1

公开(公告)日：2013-12-05

申请号：US13985533

申请日：2012-02-07

申请人： Sei Ryang Oh ,  Kyung Seop Ahn ,  Ok-Kyoung Kwon ,  Hyeong Kyu Lee ,  Joongku Lee ,  Hyouk Joung ,  Mee-Young Lee ,  Hwa-Young Son ,  Kyoung-youl Lee ,  Sang Woo Lee ,  Hang Jin ,  Wan Yi Li

发明人： Sei Ryang Oh ,  Kyung Seop Ahn ,  Ok-Kyoung Kwon ,  Hyeong Kyu Lee ,  Joongku Lee ,  Hyouk Joung ,  Mee-Young Lee ,  Hwa-Young Son ,  Kyoung-youl Lee ,  Sang Woo Lee ,  Hang Jin ,  Wan Yi Li

IPC分类号： A61K36/61

CPC分类号： A61K36/61

摘要： The present invention relates to a pharmaceutical composition for the prevention and treatment of inflammatory disease or asthma comprising the extract of Decaspermum fruticosum as an active ingredient. The extract of Decaspermum fruticosum of the present invention inhibited the increase of eosinophils in bronchoalveolar lavage fluid of the ovalbumin-induced asthma animal model, had the activity of inhibiting the secretions of immunoglobulin and chemokine (Eotaxin) in bronchoalveolar lavage fluid and blood, and inhibited the secretions of NO and TNF-α in macrophages. Therefore, the extract of Decaspermum fruticosum of the present invention can be effectively used as an active ingredient of a pharmaceutical composition for the prevention and treatment of inflammatory disease or asthma, and of a health functional food for the prevention and improvement of inflammatory disease or asthma.

摘要翻译： 本发明涉及一种用于预防和治疗炎症性疾病或哮喘的药物组合物，其包含作为活性成分的Dececpermum fruticosum的提取物。 本发明的Decaspermum fruticosum的提取物抑制卵清蛋白诱导的哮喘动物模型的支气管肺泡灌洗液中嗜酸性粒细胞的增加，具有抑制支气管肺泡灌洗液和血液中免疫球蛋白和趋化因子（Eotaxin）分泌的活性，并被抑制 NO和TNF-α在巨噬细胞中的分泌。 因此，本发明的Decaspermum fruticosum的提取物可以有效地用作预防和治疗炎性疾病或哮喘的药物组合物的活性成分，以及用于预防和改善炎性疾病或哮喘的健康功能食品 。

公开(公告)号：US08980846B2

公开(公告)日：2015-03-17

申请号：US13885986

申请日：2011-11-17

申请人： Kyung Seop Ahn ,  Ha Young Jang ,  Sei Ryang Oh ,  Hyeong Kyu Lee ,  Ok-Kyoung Kwon ,  Semi Kim ,  Jung Hee Kim ,  Doo-Young Kim

发明人： Kyung Seop Ahn ,  Ha Young Jang ,  Sei Ryang Oh ,  Hyeong Kyu Lee ,  Ok-Kyoung Kwon ,  Semi Kim ,  Jung Hee Kim ,  Doo-Young Kim

IPC分类号： A61K31/70 ,  A61K31/34 ,  A61K31/7048 ,  A61K31/343 ,  A61K36/185 ,  A23L1/30

CPC分类号： A61K31/7048 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/343 ,  A61K36/185 ,  A23V2200/314 ,  A23V2250/21 ,  A23V2250/2116

摘要： The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of Styrax japonica, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-β1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.

摘要翻译： 本发明涉及一种用于预防或治疗哮喘的药物组合物，该组合物含有作为活性成分的苯达洛尔苷A或其糖苷配基。 更特别的是，辛伐利精A化合物是从Styrax japonica的茎和吠声中分离出来的化合物，作为styraxlignolide A的糖苷配基的辛伐利汀A或homoegonol，具有改善的安全性，具有减轻体重减轻和气道高反应性的作用， 的气道中的活性氧，抑制血清和支气管肺泡灌洗液中IgE，TGF-β1和IL-17的产生，抑制支气管炎性细胞浸润，抑制哮喘中粘膜和上皮下纤维化的形成 诱导的鼠标模型。 因此，可以有效地使用辛伐利汀或同型异黄酮作为预防或治疗气道重塑进行的支气管哮喘的药物组合物的活性成分。

公开(公告)号：US20140228427A1

公开(公告)日：2014-08-14

申请号：US14122789

申请日：2012-05-24

申请人： Sei Ryang Oh ,  Kyung Seop Ahn ,  Hyeong Kyu Lee ,  Ha Young Jang ,  Ok-Kyoung Kwon ,  Jung Hee Kim ,  Ji Won Park ,  Doo-Young Kim

发明人： Sei Ryang Oh ,  Kyung Seop Ahn ,  Hyeong Kyu Lee ,  Ha Young Jang ,  Ok-Kyoung Kwon ,  Jung Hee Kim ,  Ji Won Park ,  Doo-Young Kim

IPC分类号： A61K31/352

CPC分类号： A61K31/352

摘要： The present invention relates to a pharmaceutical composition for the prevention or treatment of asthma comprising Wogonin as an active ingredient. The Wogonin of the present invention is excellent not only in relieving airway hypersensitivity that causes asthma in vivo, in inhibiting reactive oxygen species generation in the airway, and in inhibiting the infiltration of inflammatory cells in the bronchus, but also in inhibiting the generation of IgE in serum and bronchoalveolar lavage fluid, and in inhibiting the expressions of Th2 cytokines in the lung. Therefore, the Wogonin of the present invention can be effectively used as a composition for the prevention, treatment, or improvement of asthma.

摘要翻译： 本发明涉及一种用于预防或治疗哮喘的药物组合物，其包含沃可素作为活性成分。 本发明的Wogonin不仅能缓解气道在体内引起哮喘，抑制气道中的活性氧产生，抑制炎症细胞在支气管中的浸润，而且抑制IgE的产生， 在血清和支气管肺泡灌洗液中，并抑制肺中Th2细胞因子的表达。 因此，本发明的沃可素可以有效地用作预防，治疗或改善哮喘的组合物。

公开(公告)号：US20130244959A1

公开(公告)日：2013-09-19

申请号：US13885986

申请日：2011-11-17

申请人： Kyung Seop Ahn ,  Ha Young Jang ,  Sei Ryang Oh ,  Hyeong Kyu Lee ,  Ok-Kyoung Kwon ,  Semi Kim ,  Jung Hee Kim ,  Doo-Young Kim

发明人： Kyung Seop Ahn ,  Ha Young Jang ,  Sei Ryang Oh ,  Hyeong Kyu Lee ,  Ok-Kyoung Kwon ,  Semi Kim ,  Jung Hee Kim ,  Doo-Young Kim

IPC分类号： A61K31/7048 ,  A61K31/343

CPC分类号： A61K31/7048 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/343 ,  A61K36/185 ,  A23V2200/314 ,  A23V2250/21 ,  A23V2250/2116

摘要： The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of Styrax japonica, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-β1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.

摘要翻译： 本发明涉及一种用于预防或治疗哮喘的药物组合物，该组合物含有作为活性成分的苯达洛尔苷A或其糖苷配基。 更特别的是，辛伐利精A化合物是从Styrax japonica的茎和吠声分离出来的化合物，作为styraxlignolide A的糖苷配基的styraxlignolide A或homoegonol，具有改善的安全性，具有减轻体重减轻和气道高反应性的作用， 的气道中的活性氧，抑制血清和支气管肺泡灌洗液中IgE，TGF-β1和IL-17的产生，抑制支气管炎性细胞浸润，抑制哮喘诱发的粘液栓塞和上皮下纤维化形成 鼠标模型。 因此，可以有效地使用辛伐利汀或同型异黄酮作为预防或治疗气道重塑进行的支气管哮喘的药物组合物的活性成分。

公开(公告)号：US09078912B2

公开(公告)日：2015-07-14

申请号：US13807829

申请日：2011-07-01

申请人： Hyeong Kyu Lee ,  Kyung Seop Ahn ,  Yoosik Yoon ,  Byoung Whui Choi ,  Ok-Kyoung Kwon ,  Semi Kim ,  Hui Seong Kim ,  Sei Ryang Oh ,  Ji Eun Yuk ,  Ha Young Jang

发明人： Hyeong Kyu Lee ,  Kyung Seop Ahn ,  Yoosik Yoon ,  Byoung Whui Choi ,  Ok-Kyoung Kwon ,  Semi Kim ,  Hui Seong Kim ,  Sei Ryang Oh ,  Ji Eun Yuk ,  Ha Young Jang

IPC分类号： A61K39/395 ,  C12N15/11 ,  A61K31/7088 ,  C07K14/71 ,  C12Q1/68

CPC分类号： A61K31/7088 ,  A61K39/3955 ,  C07K14/71 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N2800/122 ,  G01N2800/24

摘要： The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and by D. pteronissinus extract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma.

摘要翻译： 本发明涉及用于诊断或筛选包含神经纤维蛋白（NRP）基因的哮喘的试剂盒，以及用于使用该试剂筛选哮喘治疗剂的方法。 更准确地说，本发明证实了哮喘患者和天竺葵提取物中NRP1的表达增加。 基于确认，本发明人证实，NRP1可以有效地用作哮喘治疗剂的发展的靶标，因为抑制NRP1表达导致mRNA，蛋白质，酶活性和启动子活性降低，MMP- 9关于哮喘。

公开(公告)号：US20130108652A1

公开(公告)日：2013-05-02

申请号：US13807829

申请日：2011-07-01

申请人： Hyeong Kyu Lee ,  Kyung Seop Ahn ,  Yoosik Yoon ,  Byoung Whui Choi ,  Ok-Kyoung Kwon ,  Semi Kim ,  Hui Seong Kim ,  Sei Ryang Oh ,  Ji Eun Yuk ,  Ha Young Jang

发明人： Hyeong Kyu Lee ,  Kyung Seop Ahn ,  Yoosik Yoon ,  Byoung Whui Choi ,  Ok-Kyoung Kwon ,  Semi Kim ,  Hui Seong Kim ,  Sei Ryang Oh ,  Ji Eun Yuk ,  Ha Young Jang

IPC分类号： A61K31/7088 ,  A61K39/395

CPC分类号： A61K31/7088 ,  A61K39/3955 ,  C07K14/71 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N2800/122 ,  G01N2800/24

摘要： The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and by D. pteronissinus extract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma.

摘要翻译： 本发明涉及用于诊断或筛选包含神经纤维蛋白（NRP）基因的哮喘的试剂盒，以及用于使用该试剂筛选哮喘治疗剂的方法。 更准确地说，本发明证实了哮喘患者和天竺葵提取物中NRP1的表达增加。 基于确认，本发明人证实，NRP1可以有效地用作哮喘治疗剂的发展的靶标，因为抑制NRP1表达导致mRNA，蛋白质，酶活性和启动子活性降低，MMP- 9关于哮喘。